Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine/Islatravir in Pediatric HIV-1
NCT04295772Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of islatravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co.. Started Nov 2020; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04295772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295772.